Table 5 Site-specific standardized incidence ratios of SPMs in patients with varying prior OAL subtypes
From: Second primary malignancies after ocular adnexal lymphoma diagnosis
EZML | FL | CLL/SLL | DLBCL | MCL | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Second Cancer Site | O | SIR (95%CI) | O | O/E (95%CI) | O | O/E (95%CI) | O | O/E (95%CI) | O | O/E (95%CI) |
All Sites | 75 | 1.13 (0.89–1.41) | 41 | 1.48* (1.06–2.01) | 52 | 1.52* (1.13–1.99) | 28 | 1.38 (0.92–1.99) | 12 | 1.2 (0.62–2.09) |
All Sites excluding Non-Melanoma Skin | 74 | 1.12 (0.88–1.4) | 40 | 1.45* (1.04–1.97) | 52 | 1.52* (1.14–2) | 28 | 1.38 (0.92–2) | 11 | 1.1 (0.55–1.97) |
Colon, Rectum and Anus | 5 | 0.71 (0.23–1.65) | 2 | 0.6 (0.07–2.15) | 4 | 0.88 (0.24–2.25) | 7 | 2.73* (1.1–5.63) | 1 | 0.84 (0.02–4.68) |
Respiratory System | 6 | 0.58 (0.21–1.27) | 5 | 1.12 (0.36–2.61) | 11 | 2.02* (1.01–3.62) | 0 | 0 (0–1.15) | 3 | 1.85 (0.38–5.41) |
Female Breast | 5 | 0.54 (0.18–1.26) | 3 | 0.81 (0.17–2.37) | 0 | 0.00* (0–0.75) | 5 | 1.73 (0.56–4.04) | 1 | 1.02 (0.03–5.7) |
Kidney | 5 | 2.7 (0.88–6.3) | 0 | 0 (0–5.41) | 2 | 2.72 (0.33–9.81) | 3 | 6.28* (1.3–18.37) | 1 | 3.87 (0.1–21.55) |
Cranial Nerves Other Nervous System | 0 | 0 (0–125.28) | 1 | 87.65* (2.22–488.37) | 1 | 68.95* (1.75–384.18) | 0 | 0 (0–418.03) | 0 | 0 (0–857.12) |
Thyroid | 2 | 2.01 (0.24–7.25) | 1 | 3.77 (0.1–21.02) | 0 | 0 (0–12.59) | 2 | 9.64* (1.17–34.84) | 0 | 0 (0–43.31) |
All Lymphatic and Hematopoietic Diseases | 19 | 3.10* (1.87–4.85) | 14 | 5.62* (3.07–9.43) | 19 | 6.58* (3.96–10.27) | 4 | 2.16 (0.59–5.53) | 0 | 0 (0–4.17) |
Non-Hodgkin Lymphoma | 14 | 4.75* (2.59–7.96) | 9 | 7.51* (3.43–14.25) | 12 | 8.73* (4.51–15.25) | 2 | 2.27 (0.27–8.2) | 0 | 0 (0–9.03) |
NHL - Nodal | 9 | 4.69* (2.15–8.91) | 3 | 3.73 (0.77–10.9) | 2 | 2.13 (0.26–7.68) | 2 | 3.4 (0.41–12.29) | 0 | 0 (0–13.47) |
NHL - Extranodal | 5 | 4.84* (1.57–11.3) | 6 | 15.21* (5.58–33.12) | 10 | 23.03* (11.04–42.36) | 0 | 0 (0–12.59) | 0 | 0 (0–27.36) |
Leukemia | 5 | 2.54 (0.82–5.93) | 3 | 3.59 (0.74–10.48) | 5 | 5.14* (1.67–12) | 1 | 1.59 (0.04–8.88) | 0 | 0 (0–12.44) |
Acute Non-Lymphocytic Leukemia (ANLL) | 2 | 3.09 (0.37–11.17) | 1 | 3.79 (0.1–21.1) | 3 | 9.57* (1.97–27.98) | 1 | 4.99 (0.13–27.79) | 0 | 0 (0–38.77) |
Acute Myeloid Leukemia | 1 | 1.74 (0.04–9.68) | 1 | 4.43 (0.11–24.67) | 3 | 11.60* (2.39–33.91) | 1 | 5.87 (0.15–32.72) | 0 | 0 (0–45.66) |
Acute Monocytic Leukemia | 1 | 35.06 (0.89–195.36) | 0 | 0 (0–296.17) | 0 | 0 (0–237.19) | 0 | 0 (0–386.43) | 0 | 0 (0–803.64) |
Chronic Myeloid Leukemia | 1 | 4.01 (0.1–22.34) | 0 | 0 (0–35.16) | 0 | 0 (0–29.13) | 0 | 0 (0–45.86) | 0 | 0 (0–97.75) |
Other Myeloid/Monocytic Leukemia | 0 | 0 (0–158.88) | 1 | 81.67* (2.07–455.04) | 0 | 0 (0–223.64) | 0 | 0 (0–372.52) | 0 | 0 (0–810.25) |